BPM 28740
Alternative Names: BPM-28740Latest Information Update: 25 Aug 2025
At a glance
- Originator Berg Pharma
- Developer BPG Bio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2025 Discontinued - Preclinical for Cancer in USA (unspecified route) before August 2025 (BPG Bio pipeline, August 2025)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 06 Dec 2018 Preclinical trials in Cancer in USA (unspecified route) (Berg Pharma pipeline, December 2018)